

<b>DATE:</b>	9 January 2023
<b>TO:</b>	Oncologists, Province Wide
<b>FROM:</b>	Edmonton Zone Immunohistochemistry Laboratory, Alberta Precision Laboratories (APL)
<b>RE:</b>	<b>PD-L1 Triple Negative Breast Cancer and Cervical Cancer</b>

---

## PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

---

### Key Message

- PD-L1 biomarker immunohistochemistry (IHC) testing is available for adult patients with locally recurrent unresectable or metastatic **triple-negative breast cancer (TNBC)**, who have not received prior chemotherapy for metastatic disease.
- PD-L1 biomarker IHC testing is also available for persistent, recurrent or metastatic **cervical cancer**.
- Requests for testing can be made by Oncologists.

### Background

- The pharmaceutical company Merck has provided compassionate funding for PD-L1 PharmDx 22C3 TNBC and Cervical Cancer.
- PD-L1 IHC (22C3 pharm Dx) with the combined positive score (CPS) utilized herein has been developed for use of Pembrolizumab in combination with chemotherapy with locally recurrent unresectable or metastatic **triple-negative breast cancer (TNBC)**, who have not received prior chemotherapy for metastatic disease and whose tumors express PD-L1(Keynote-355).
- PD-L1 IHC (22C3 pharm Dx) with the combined positive score (CPS) utilized herein has been developed for use of Pembrolizumab in persistent, recurrent or metastatic **cervical cancer** and is not interchangeable with other PD-L1 assays (Keynote-826).

### Action Required

- Edmonton: Requests for testing are to be forwarded to Edmonton Zone IHC Lab. Fax: 780-429-2819
- Calgary: Requests for testing are to be forwarded to the Consult Desk Fax: 403-944-4748

**Effective**                      **January 3, 2023**

### Questions/Concerns

- Dr. Gilbert Bigras [Gilbert.Bigras@albertaprecisionlabs.ca](mailto:Gilbert.Bigras@albertaprecisionlabs.ca) 780-432-8445

### This bulletin has been reviewed and approved by

- Dr. Carolyn O'Hara, Interim Chief Medical Laboratory Officer, Alberta Precision Laboratories